CUR Share Price

Open 0.01 Change Price %
High 0.02 1 Day 0.01 100.00
Low 0.01 1 Week 0.00 0.00
Close 0.02 1 Month 0.00 0.00
Volume 219000 1 Year 0.01 100.00
52 Week High 0.02
52 Week Low 0.01
CUR Important Levels
Resistance 2 0.03
Resistance 1 0.03
Pivot 0.02
Support 1 0.01
Support 2 0.01
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
RY 93.66 -1.90%
RY 93.66 -1.90%
HCG 8.02 33.89%
HCG 8.02 33.89%
HCG 8.02 33.89%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
CAM 12.19 96.61%
CAM 12.19 96.61%
CAM 12.19 96.61%
CAM 12.19 96.61%
CAM 12.19 96.61%
CAM 12.19 96.61%
More..
TSE Canada Top Losers Stocks
LRT-UN 0.03 -25.00%
GBV 0.46 -24.59%
HBP 0.76 -18.28%
HBP 0.76 -18.28%
AVP 0.06 -14.29%
AVP 0.06 -14.29%
AVP 0.06 -14.29%
AVP 0.06 -14.29%
CTU-A 0.19 -9.52%
GGA 0.10 -9.09%
More..

Diagnocure Inc (TSE: CUR)

CUR Technical Analysis 5
As on 6th Jun 2016 CUR Share Price closed @ 0.02 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.10 & Strong Sell for SHORT-TERM with Stoploss of 0.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
CUR Target for April
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CUR Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.diagnocure.com
CUR Address
CUR
4535 Wilfrid-Hamel Boulevard
Suite 250
Quebec, QC G1P 2J7
Canada
Phone: 418-527-6100
Fax: 418-527-0240
CUR Latest News
Learn details of the global companion diagnostic cancer biomarkers market   WhaTech   - 07th Apr 17
Global Companion Diagnostic Cancer Biomarkers Market – Global Market Insights ...   Medgadget (blog)   - 05th Apr 17
Global Drugs & Diagnostics for Hematological Disorders Market Worth USD 124.3 ...   Business Wire (press release)   - 30th Sep 16
Diagnocure announces its decision to proceed with the voluntary Liquidation ...   PR Newswire (press release)   - 15th Apr 16
DiagnoCure announces closing of the PCA3 Asset Sale transaction and special ...   Canada NewsWire (press release)   - 18th Feb 16
DiagnoCure announces the execution of an Asset Purchase Agreement   PR Newswire (press release)   - 24th Dec 15
Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker ...   PR Newswire (press release)   - 30th Jul 15
Companion Diagnostics in Personalized Medicine and Cancer Therapy   PR Newswire (press release)   - 06th Aug 14
FDA approves PROGENSA® PCA3 assay   PR Newswire (press release)   - 15th Feb 12
The Future of Molecular Diagnostics: Innovative Technologies Driving Market ...   PR Newswire (press release)   - 08th Nov 10
Interactive Technical Analysis Chart Diagnocure Inc ( CUR TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Diagnocure Inc
CUR Business Profile
DiagnoCure Inc., a life sciences company, develops and commercializes cancer diagnostic tests for the detection and management of cancer. The company primarily focuses on molecular diagnostic tests. It offers PCA3 test for the diagnosis of prostate cancer; and GCC marker, Previstage GCC staging test, GCC monitoring blood test, Shc proteins, and scientific publications for use in colorectal cancer management. The company was founded in 1994 and is headquartered in Quebec, Canada.